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Abstract. Drug delivery systems were developed from coralline hydroxyapatite (HAp) and 
biodegradable polylactic acid (PLA). Gentamicin (GM) was loaded in either directly to PLA 
(PLAGM) or in HAp microspheres. Drug loaded HAp was used to make thin film composites 
(PLAHApGM). Dissolution studies were carried out in phosphate buffered saline (PBS). The 
release profiles suggested that HAp particles improved drug stabilization and availability as well 
controlled the release rate. The release also displays a steady state release. In vitro studies in human 
Adipose Derived Stem Cells (hADSCs) showed substantial quantities of cells adhering to 
hydroxyapatite containing composites. The results suggested that the systems could be tailored to 
release different clinical active substances for a wide range of biomedical applications. 
Introduction 
Tissue engineering and advanced medical technologies have been very effective tools to 
improve the quality of human life. The benefits of bioceramic materials used for the repair and 
reconstruction of disease or damage afflicted areas of the musculoskeletal system have been broadly 
implemented [1]. During the last two decades the development of bioceramic composites capable of 
releasing clinical active materials by reproducible and predictable kinetics has been a clinical and 
scientific endeavour. Drug release systems have been proved to provide outstanding alternative to 
conventional clinical therapies. The advancement in both science and biomaterial design and 
engineering, more sophisticated therapeutic agent release systems have been developed with 
improved capabilities and performances for the treatment of resilient diseases such as 
musculoskeletal disorders and bone related diseases. There are also possibilities to develop drug 
release systems with more efficiency and rational drug delivery platforms featuring up-to-the-
minute technological capabilities [2]. Drug delivery technology presents an interesting 
interdisciplinary challenge for pharmaceutical, chemical engineering, biomaterials and medical 
communities [3]. In general, a biomaterial that will act as a drug carrier must have the ability to 
incorporate a drug, to retain it in a specific site, and to deliver it progressively with time to the 
surrounding tissues. Furthermore, it would be advantageous if the material is injectable or 
alternatively coatable on an implant and most importantly a biodegradable [4] 
Usage of biodegradable materials in designing drug release devices addresses these 
challenges by providing outstanding capability of performing localized and controlled delivery of 
drugs at different parts of the host body. Biodegradable polymer films loaded with gentamicin have 
been developed to serve as “coatings” for fracture fixation devices and prevent implant-associated 
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infections [5]. The use of biodegradable polymer films is advantageous due to its propensity to 
uptake and release antibiotics, as a consequence of its degradability. Although their drug release 
rates are high, they could be tailored to form biocomposites with different biodegradability rates by 
incorporating other materials. Biodegradable polymer-bioceramic composites suits this hypothesis a 
great deal because of the bioactive nature of ceramic materials, specifically calcium phosphate 
based materials, which promotes bone tissue growth. Incorporation of bioceramics derived from 
coral in the polymer will improve not only controlled drug release but also bioactivity and tissue 
regeneration, especially in orthopaedic and maxillofacial applications. 
This research is aimed at developing and testing gentamicin (due to its widely used for the 
treatment of bacterial infection)  loaded hydroxyapatite particles (HAp) within thin film polylactic 
acid (PLA) biocomposites as slow drug delivery devices for the treatment of bone and implant-
related infections. 
Experimental 
Materials. Coral skeleton samples were obtained from the Great Barrier Reef shoreline, QLD 
Australia. Gentamicin sulfate, Clodronate (Dichloromethylenediphosphonic acid disodium salt), 
Chloroform diammonium hydrogen phosphate (NH4)2HPO4, 98%), and sodium hypochlorite 
(NaClO), were obtained from Sigma Aldrich, Castle Hill, Australia. 
Methods. Coralline materials were hydrothermally converted to hydroxyapatite based on the 
procedures described in [6, 7]. Drug loading and in-vitro drug release from PLAHAp composites 
followed the procedures described in [6, 8]. Bioceramic composites were produced by solution 
casting method. Briefly, the film composites were loaded with 10 % (w/w) and the release was 
studied in buffer solutions at physiological conditions. Drug release study from PLA thin film 
composites was conducted under SINK conditions in phosphate buffered saline (PBS) ((0.1 M, 
Na3N 0.1%, pH 7.4) at 37 ± 0.1 °C) for gentamicin and in Tris-HCl buffer ((0.1 M, pH 7.4) at 37 ± 
0.1 oC) for clodronate (because PBS will interfere with 31P quantification) in a temperature 
controlled water bath shaker running at constant speed of 100 rpm. Each sampling time had its own 
independent samples under the same conditions and experiments were respectively terminated after 
sampling. Gentamicin concentrations in the solution were determined by Cary 100 UV-Vis 
spectrophotometer (Agilent Technologies, Victoria, Australia, Cary Series UV-Vis 
Spectrophotometer) at the maximum absorbance of gentamicin-o-phthaldialdehyde complex, λmax = 
332 nm, using procedures described in [5, 9]. Ophthaldialdehyde reagent was prepared by 
dissolving 2.5 g ophthaldialdehyde in 62.5 mL methanol and adding with 3 mL 2-
hydroxyethylmercaptan to 560 mL 0.04 M sodium borate in distilled water. 2 mL gentamicin 
solution, 2 mL o-phthaldialdehyde reagent were reacted for 45 min at room temperature. The 
absorbance, which corresponds to the gentamicin concentration, was then measured at 332 nm. 
Stem Cell attachment. Adult hADSCs tissue culture was conducted under asceptic sterile 
conditions in a class II laminar flow hood (Clyde-Apac BH2000 series). hADSCs were cultured till 
sub-confluence at  5x104 cells/cm2 T25 culture flask (Nunc) in D-MEM Glutmax/F12 (Gibco) with
10% FBS (Invitrogen) and incubated at 37o C at 5% CO2. Subsequently cells were passaged and
diluted to for the seeding density 1x104 cells/cm to be placed on PLA and PLAGM for 10 days for
continual growth and adherence test. Non-adherent cells are eliminated by replacing the media 
every 2 days for normal cellular growth. At 10 days media was decanted, cells washed in PBS, 
fixed in 4% formalin, washed in di-ionized water (dH2O) and dehydrated for SEM. 
Results and Discussion 
Drug release from PLA and PLA-HAp composite is not only due to PLA degradation but also 
the diffusion of the drug entrapped into the polymer matrix, which plays an important role 
depending on the extension of the experiments. Fig.1 shows drug release profiles composed of five 
stages for PLAGM and PLAHApGM thin film composites. It is possible to appreciate different 
shapes of the release curves depending on the type of drugs and release medium. The release time 
was also enough to appreciate significant de gradation of the polymer matrix as shown in Fig. 2. The 
assessment of kinetic release from drng delive1y devices provides the confidence to predict the 
release behaviour before the release systems are realized. The release kinetic study was assessed by 
model dependent method. Based on number of kinetic models available in literature, the selected 
model described the overall release of drng from the dosage fonns. 
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Figure 1: Release profile of gentamicin from PLAGM and PLAHApGM thin films 
In the release profiles of drngs from degradable polymer matrix the most sustained release paii is 
by degradation of the polymer matrix. Table 1 shows time range of each release stage for 
gentamicin (these values ai·e an approximation considering the shape of the release profiles, the 
final time of one stage occurs with the initial time of the next one). Each stage time goes with the 
assumptions that the dmg is homogeneously distributed in the matrix and therefore homogeneously 
release of the drngs from the matl'ix. 
Table 1: Specific time frames for different release stages and their numerical values for gentamicin 
(Five stages) 
NameofDrug 
Gentamicin 
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Figure 2: SEM picture of gentamicin loaded PLAGM and PLAHApGM before and after three 
weeks of drng release in PBS revealing degraded m01phologies. 
Table 1: Modelled dissolution characteristics of the mean dissolution profile 
Model Model expression PLAGM PLAHApGM 
Korsmeyer-Peppas F = ktn r2 0.992 0.962 
n 0.282 1.315 
The release of gentamicin from these devices seem to follow semi-empirical equation describe 
by Korsmeyer-Peppas model. Neve1theless, the 'n' coefficient obtained for PLAGM and 
PLAHApGM (Table 2), indicates that somehow a number of different mechanisms might control 
the release. Thus, the release of gentamicin contained from PLA matrix seems to be mainly 
contrnlled by diffusion whereas for PLAHApGM is possibly mixture of diffusion, super case II 
mechanism and possible combination of other mechanisms of trnnsp01t which control drng release. 
Fig. 3 presents SEM pictures showing in vitro studies using stem cell investigations. The 
m01phology and attachment of (hADSC) seeded on PLA thin film composites. The results show 
high density of cellular attachment on hydroxyapatite containing composites such as PLAHAp and 
PLAHApGM samples but none on PLA and PLAGM (not shown) composites. PLA has an alkyl 
pendant group (CHr) in its backbone, which makes the polymer more hydrophobie, and tends to 
denaturalize proteins responsible for cell binding and adhesion, while hydroxyapatite is 
osteoconductive material. Gentamicin has NH2- group, which with CH3- on the polymer backbone 
reduce any chance for protein binding on the surface. This was evident because these samples (PLA 
and PLGM) do not show any cell on their surfaces. 
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Figure 3: SEM pictures of stem cell cultured PLA thin film composites for 10 days, showing 
attachment and morphology of cells. 
Figure 4: SEM picture of cell cultured samples coated with polylysine a) PLA b) PLAGM 
In order to confirm the lack of protein adsorption on the surface of PLA and PLAGM 
samples, we coated them with poly-L-lysine (Sigma Aldrich, Australia) as an attachment factor to 
enhance the electrostatic interaction between negatively charged ions of the cell membrane and 
positively-charged ions of the culture surface by increasing the number of positively-charged sites 
available for cell binding. The results suggest that cells were able to attach on the PLA and PLAGM 
surfaces after coating in less than 24 hours (Fig. 4). 
Conclusions 
Controlled drugs release successfully achieved for gentamicin containing composites with 
defined dissolution kinetics. This in-vitro study shows the potential of PLA-bioceramic film 
composites as effective local drug delivery devices for biomedical applications. In addition, they 
can generally be used in surgery to prevent infections caused by bacterial.  
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